EverSource Wealth Advisors LLC Acquires 374 Shares of Amgen Inc. (NASDAQ:AMGN)

EverSource Wealth Advisors LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 1.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,520 shares of the medical research company’s stock after acquiring an additional 374 shares during the period. EverSource Wealth Advisors LLC’s holdings in Amgen were worth $9,814,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. United Community Bank acquired a new position in shares of Amgen during the fourth quarter valued at about $29,000. Horizon Financial Services LLC acquired a new position in Amgen in the 1st quarter valued at approximately $28,000. nVerses Capital LLC acquired a new position in Amgen in the 2nd quarter valued at approximately $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $33,000. Finally, FSA Wealth Management LLC increased its position in shares of Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.4 %

AMGN opened at $337.38 on Friday. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The stock has a market capitalization of $180.98 billion, a PE ratio of 48.20, a PEG ratio of 2.93 and a beta of 0.61. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The firm has a 50-day moving average price of $329.57 and a two-hundred day moving average price of $305.82.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the company posted $5.00 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.67%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is 128.57%.

Analysts Set New Price Targets

Several research analysts recently commented on AMGN shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. Bank of America upped their target price on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. TD Cowen raised their price target on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada upped their price objective on Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $327.28.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.